The University of Chicago’s Department of Ophthalmology is now Offering a Newly FDA-Approved Treatment to Stop Progressive Vision Loss in Patients Diagnosed with Keratoconus

By Nicole Mazzone

We are now accepting patients who may be candidates for a newly FDA-approved outpatient procedure known as “corneal cross-linking.” Widely available in Europe and Canada for years, corneal cross-linking received FDA-approval in the United States in April of this year. This procedure is a treatment to prevent the progression of keratoconus, a degenerative eye condition in which the normally round, dome-like cornea—the clear front window of the eye—becomes thin and develops a cone-like bulge. The irregular shape caused by keratoconus distorts a person’s vision, which can make some activities—such as driving, watching television, or reading—difficult.  Left untreated, it can progress to the level of legal blindness. Many people in the past with keratoconus have undergone corneal transplants, but with corneal cross-linking, there may be an alternative to invasive surgery.


Left: normal cornea; right: cornea with keratoconus.

“This procedure actually halts the progression of the disease,” says Department of Ophthalmology and Visual Science Chair, Dr. Kathryn Colby. “Our European colleagues have been using this technique for years to prevent vision loss from keratoconus.”

To schedule an appointment, please call 773-702-3937.

Read Corneal Cross-linking FAQS